Edward N. Wilson
YOU?
Author Swipe
View article: Biomarker‐informed characterization of an <i>ABCA7</i> tandem repeat expansion in a family with early‐onset Alzheimer’s Disease
Biomarker‐informed characterization of an <i>ABCA7</i> tandem repeat expansion in a family with early‐onset Alzheimer’s Disease Open
Background ATP‐binding cassette transporter A7 ( ABCA7 ) has been genetically implicated in Alzheimer’s Disease (AD). A recent study by De Roeck et al. (2018) suggested a variable number tandem repeat (VNTR) in intron 18 of ABCA7 is a driv…
View article: Plasma proteomic signatures of preclinical Alzheimer’s disease biomarkers and memory in clinically unimpaired older adults
Plasma proteomic signatures of preclinical Alzheimer’s disease biomarkers and memory in clinically unimpaired older adults Open
Background Multianalyte plasma proteomic panels that can accurately detect initial AD pathology in preclinical populations and simultaneously measure related biological processes relevant for disease risk are critical for advancing early d…
View article: Plasma phosphorylated tau 217 detects amyloid-β in Neuronal Synuclein Disease
Plasma phosphorylated tau 217 detects amyloid-β in Neuronal Synuclein Disease Open
Background Multiple proteinopathies commonly coexist in neurodegenerative diseases, therefore it is critical to understand plasma biomarker performance to detect proteinopathies in these complex diseases. While plasma biomarkers can accura…
View article: Effects of α-synuclein pathology in normal aging and Alzheimer’s disease
Effects of α-synuclein pathology in normal aging and Alzheimer’s disease Open
Objective α-synuclein is the hallmark pathology of Parkinson’s disease and dementia with Lewy bodies, described together as Lewy body disease (LBD). α-synuclein is also commonly observed in the context of Alzheimer’s disease (AD). Here we …
View article: Synergistic effects of <i>APOE</i> ε4 and Alzheimer’s pathology on the neural correlates of episodic remembering in cognitively unimpaired older adults
Synergistic effects of <i>APOE</i> ε4 and Alzheimer’s pathology on the neural correlates of episodic remembering in cognitively unimpaired older adults Open
Amyloid-β (Aβ) and tau pathology begin accumulating decades before clinical symptoms and are influenced by APOE ε4, a key genetic risk factor for Alzheimer’s disease (AD). Although the presence of Aβ, tau, and APOE ε4 are thought to impact…
View article: Top-down attention and Alzheimer’s pathology affect cortical selectivity during learning, influencing episodic memory in older adults
Top-down attention and Alzheimer’s pathology affect cortical selectivity during learning, influencing episodic memory in older adults Open
Effective memory formation declines in human aging. Diminished neural selectivity—reduced differential responses to preferred versus nonpreferred stimuli—may contribute to memory decline, but its drivers remain unclear. We investigated the…
View article: Parkinson’s disease is characterized by vitamin B6-dependent inflammatory kynurenine pathway dysfunction
Parkinson’s disease is characterized by vitamin B6-dependent inflammatory kynurenine pathway dysfunction Open
Recent studies demonstrate that Parkinson’s disease (PD) is associated with dysregulated metabolic flux through the kynurenine pathway (KP), in which tryptophan is converted to kynurenine (KYN), and KYN is subsequently metabolized to neuro…
View article: A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer’s disease
A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer’s disease Open
Rates of cognitive decline in Alzheimer's disease (AD) are extremely heterogeneous. Although biomarkers for amyloid-beta (Aβ) and tau proteins, the hallmark AD pathologies, have improved pathology-based diagnosis, they explain only 20-40% …
View article: A single-cell atlas to map sex-specific gene-expression changes in blood upon neurodegeneration
A single-cell atlas to map sex-specific gene-expression changes in blood upon neurodegeneration Open
The clinical course and treatment of neurodegenerative disease are complicated by immune-system interference and chronic inflammatory processes, which remain incompletely understood. Mapping immune signatures in larger human cohorts throug…
View article: Plasma Aβ<sub>42</sub>/Aβ<sub>40</sub> is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum
Plasma Aβ<sub>42</sub>/Aβ<sub>40</sub> is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum Open
INTRODUCTION The availability of amyloid beta (Aβ) targeting therapies for Alzheimer's disease (AD) is increasing the demand for scalable biomarkers that are sensitive to early cerebral Aβ accumulation. METHODS We evaluated fully‐automated…
View article: 18F-PI-2620 Tau PET is associated with cognitive and motor impairment in Lewy body disease
18F-PI-2620 Tau PET is associated with cognitive and motor impairment in Lewy body disease Open
Co-pathology is frequent in Lewy body disease, which includes clinical diagnoses of both Parkinson’s disease and dementia with Lewy bodies. Measuring concomitant pathology in vivo can improve clinical and research diagnoses and prediction …
View article: Top-down attention and Alzheimer's pathology impact cortical selectivity during learning, influencing episodic memory in older adults
Top-down attention and Alzheimer's pathology impact cortical selectivity during learning, influencing episodic memory in older adults Open
Human aging affects the ability to remember new experiences, in part, because of altered neural function during memory formation. One potential contributor to age-related memory decline is diminished neural selectivity -- i.e., a decline i…
View article: A Multi‐Pathway Blood‐Based Biomarker Panel Reveals Stereotyped Progression of Blood Biomarker Changes in Alzheimer’s Disease
A Multi‐Pathway Blood‐Based Biomarker Panel Reveals Stereotyped Progression of Blood Biomarker Changes in Alzheimer’s Disease Open
Background Blood‐based biomarkers have emerged as critical tools for detecting Alzheimer’s disease (AD) pathologies decades prior to the onset of clinical symptoms. However, research has been slow to realize the enormous potential of blood…
View article: Genetic Analysis of an Amyloid PET‐Negative Autopsy‐Confirmed Alzheimer's Pedigree
Genetic Analysis of an Amyloid PET‐Negative Autopsy‐Confirmed Alzheimer's Pedigree Open
Background Alzheimer's disease (AD) is the most common form of dementia. Neuropathologically, AD stands out as a mixed proteinopathy. Beta‐amyloid and tau biomarkers can now add in‐vivo support to the AD diagnosis. Rarely, a patient with A…
View article: Occipital amyloid‐β burden and clinical correlates in Lewy body disease
Occipital amyloid‐β burden and clinical correlates in Lewy body disease Open
Background Accurate assessment of amyloid‐ß burden in Lewy body disease (LBD) is crucial due to the frequent co‐occurrence of amyloidosis. Current amyloid‐ß PET imaging protocols often overlook the occipital lobe, a relevant area in Lewy b…
View article: Effects of α‐synuclein pathology in Alzheimer’s disease and normal aging
Effects of α‐synuclein pathology in Alzheimer’s disease and normal aging Open
Background α‐Synuclein is the hallmark pathology of Parkinson’s disease and dementia with Lewy bodies, described together as Lewy body disease (LBD). α‐Synuclein is also commonly observed in the context of Alzheimer’s disease (AD). Here we…
View article: Multi‐cohort cerebrospinal fluid proteomics identifies robust molecular signatures for asymptomatic and symptomatic Alzheimer’s disease
Multi‐cohort cerebrospinal fluid proteomics identifies robust molecular signatures for asymptomatic and symptomatic Alzheimer’s disease Open
Background Changes in Amyloid‐β (A) and hyperphosphorylated Tau (T) in the brain and cerebrospinal fluid (CSF) precedes AD symptoms, making the CSF proteome a potential avenue to understand disease pathophysiology and facilitate reliable d…
View article: Comparing the diagnostic performance of plasma pTau181 and pTau217 for the identification of Alzheimer’s disease co‐pathology in Lewy Body Disease
Comparing the diagnostic performance of plasma pTau181 and pTau217 for the identification of Alzheimer’s disease co‐pathology in Lewy Body Disease Open
Background Lewy body disease (LBD) often co‐occurs with Alzheimer’s disease neuropathological change (ADNC), which can be detected using plasma pTau181 and pTau217. Few studies have investigated these biomarkers in LBD, nor have studies in…
View article: Occipital amyloid‐β burden and clinical correlates in Lewy body disease
Occipital amyloid‐β burden and clinical correlates in Lewy body disease Open
Background Accurate assessment of amyloid‐β burden in Lewy body disease (LBD) is crucial due to the frequent co‐occurrence of amyloidosis. Current amyloid‐β PET imaging protocols often overlook the occipital lobe, a relevant area in Lewy b…
View article: Integration of GWAS and cerebrospinal fluid proteogenomics identifies proteins for AD and shared dysregulated mechanisms in other neurological traits
Integration of GWAS and cerebrospinal fluid proteogenomics identifies proteins for AD and shared dysregulated mechanisms in other neurological traits Open
Background Cerebrospinal fluid (CSF) is a valuable resource for the study and diagnosis of neurological diseases, but few studies have comprehensively characterized the genetic determinants of CSF protein levels that may contribute to the …
View article: Genetic Analysis of an Amyloid PET‐Negative Autopsy‐Confirmed Alzheimer’s Pedigree
Genetic Analysis of an Amyloid PET‐Negative Autopsy‐Confirmed Alzheimer’s Pedigree Open
Background Alzheimer’s disease (AD) is the most common form of dementia. Neuropathologically, AD stands out as a mixed proteinopathy. Beta‐amyloid and tau biomarkers can now add in‐vivo support to the AD diagnosis. Rarely, a patient with A…
View article: Synapse protein signatures in cerebrospinal fluid and plasma predict cognitive maintenance versus decline in Alzheimer’s disease
Synapse protein signatures in cerebrospinal fluid and plasma predict cognitive maintenance versus decline in Alzheimer’s disease Open
Rates of cognitive decline in Alzheimer’s disease (AD) are extremely heterogeneous, with ages of symptom onset ranging from age 40-100 years and conversion from mild cognitive impairment to AD dementia taking 2-20 years. Development of bio…
View article: Restoring hippocampal glucose metabolism rescues cognition across Alzheimer’s disease pathologies
Restoring hippocampal glucose metabolism rescues cognition across Alzheimer’s disease pathologies Open
Impaired cerebral glucose metabolism is a pathologic feature of Alzheimer Disease (AD), and recent proteomic studies highlight a disruption of glial carbohydrate metabolism with disease progression. Here, we report that inhibition of indol…
View article: Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease
Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease Open
Objective To determine whether plasma phosphorylated‐Tau181 (pTau181) could be used as a diagnostic biomarker of concurrent Alzheimer's disease neuropathologic change (ADNC) or amyloidosis alone, as well as a prognostic, monitoring, and su…
View article: Plasma pTau181 reveals a pathological signature that predicts cognitive outcomes in Lewy body disease
Plasma pTau181 reveals a pathological signature that predicts cognitive outcomes in Lewy body disease Open
Lewy body disease (LBD) often co-exists with Alzheimer’s disease (AD), influencing disease progression, cognitive decline, and neurodegeneration. This study aims to determine whether plasma phosphorylated-Tau181 (pTau181) could be used as …
View article: CSF proteomic profiling with amyloid/tau positivity identifies distinctive sex-different alteration of multiple proteins involved in Alzheimer’s disease
CSF proteomic profiling with amyloid/tau positivity identifies distinctive sex-different alteration of multiple proteins involved in Alzheimer’s disease Open
In Alzheimer’s disease (AD), the most common cause of dementia, females have higher prevalence and faster progression, but sex-specific molecular findings in AD are limited. Here, we comprehensively examined and validated 7,006 aptamers ta…